Page last updated: 2024-10-29

ketoconazole and Apparent Mineralocorticoid Excess Syndrome

ketoconazole has been researched along with Apparent Mineralocorticoid Excess Syndrome in 1 studies

1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Luque-Ramírez, M1
Ortiz-Flóres, AE1
Nattero-Chávez, L1
Escobar-Morreale, HF1

Other Studies

1 other study available for ketoconazole and Apparent Mineralocorticoid Excess Syndrome

ArticleYear
Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease.
    Clinical endocrinology, 2020, Volume: 92, Issue:1

    Topics: 14-alpha Demethylase Inhibitors; Female; Humans; Ketoconazole; Middle Aged; Mineralocorticoid Excess

2020
Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease.
    Clinical endocrinology, 2020, Volume: 92, Issue:1

    Topics: 14-alpha Demethylase Inhibitors; Female; Humans; Ketoconazole; Middle Aged; Mineralocorticoid Excess

2020
Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease.
    Clinical endocrinology, 2020, Volume: 92, Issue:1

    Topics: 14-alpha Demethylase Inhibitors; Female; Humans; Ketoconazole; Middle Aged; Mineralocorticoid Excess

2020
Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease.
    Clinical endocrinology, 2020, Volume: 92, Issue:1

    Topics: 14-alpha Demethylase Inhibitors; Female; Humans; Ketoconazole; Middle Aged; Mineralocorticoid Excess

2020